Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

被引：37

作者：

Dhalla, Irfan A.

Mamdani, Muhammad M.

Simor, Andrew E.

Kopp, Alex

Rochon, Paula A.

Juurlink, David N.

机构：

[1] Univ Toronto, Dept Med, Toronto, ON, Canada

[2] Univ Toronto, Dept Pharm, Toronto, ON, Canada

[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[4] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada

[5] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada

[6] Sunnybrook Hlth Sci Ctr, Dept Microbiol, Toronto, ON, Canada

[7] Baycrest Res Ctr Aging & Brain, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada

[8] Inst Clin Evaluat Sci, Toronto, ON, Canada

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 09期

关键词：

D O I：

10.1128/AAC.00592-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.

引用

页码：3216 / 3219

页数：4

共 31 条

[1] Long term MI outcomes at hospitals with or without on-site revascularization [J].